Skip to main content
Avivagen Inc. logo

Avivagen Inc. — Investor Relations & Filings

Ticker · VIV ISIN · CA05382F2026 TSXV Manufacturing
Open in API
Filings indexed 552 across all filing types
Latest filing 2021-03-08 Regulatory Filings
Country CA Canada
Listing TSXV VIV

About Avivagen Inc.

http://www.avivagen.com

Avivagen Inc. was a life sciences corporation focused on developing and commercializing natural health products for livestock, companion animals, and humans. The company specialized in feed additives designed to support immune function and promote growth in animals, emphasizing science-based validation through clinical trials. On April 23, 2024, Avivagen Inc. filed a voluntary assignment in bankruptcy, and a trustee was appointed to manage the proceedings.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2021-03-08 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a proposed extension of the expiration date of warrants issued by Avivagen Inc. It discusses the terms of the warrants, the request for approval from the TSX Venture Exchange, and provides background information about the company and its products. There is no financial data, no detailed report, no management discussion, or regulatory filing content. The document is an update on a capital market instrument (warrants) and their expiration extension, which fits the category of Capital/Financing Update (CAP). The document length is about 5123 characters, which is sufficient for a detailed announcement but does not contain financial statements or report content. Therefore, the correct classification is CAP with high confidence.
2021-03-05 English
News release - English.pdf
Regulatory Filings
2021-03-04 English
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a press release announcing Avivagen Inc.'s unaudited financial results for the first quarter ending January 31, 2021. It includes detailed financial data such as revenues, comprehensive loss, assets, liabilities, and shareholders' deficit for the quarter. It also discusses significant financing activities completed after the quarter, including a bought deal financing of $7.5 million. The document references the filing of the unaudited financial statements and Management's Discussion and Analysis (MD&A) on SEDAR, indicating that this announcement summarizes the quarterly financial results. The presence of substantive financial data and analysis for a period shorter than a full fiscal year (quarterly) aligns with the definition of an Interim / Quarterly Report (IR). The document is not merely an announcement of a report publication or a certification, but contains actual financial results and management commentary. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2021
2021-03-03 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification by the CFO of Avivagen Inc. regarding the interim financial report and interim MD&A for the period ended January 31, 2021. It is a Form 52-109FV2, which is a certification of interim filings for a venture issuer. The document does not contain actual financial data or the interim report itself, but rather a certification statement about the interim filings. According to the rules, certifications or attestations referencing reports but not containing substantive financial data should be classified as Regulatory Filings (RNS). The document length is short (2997 characters), and it is clearly a certification, not the interim report itself.
2021-03-03 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate. It is a certification by the CEO regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended January 31, 2021. The document does not contain actual financial data or substantive financial analysis but is an officer certification related to interim filings. According to the Certification Rule, such certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself. The document length is short (2995 characters), and it is clearly a certification letter, not the interim report or MD&A itself.
2021-03-03 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.